Thelansis

Polymyositis (PM) and Dermatomyositis (DM) are autoimmune muscle diseases that lead to muscle inflammation, weakness in the proximal muscles, and additional symptoms. Both muscle weakness and a skin rash characterize DM. While these conditions share common clinical and histological features, such as muscle weakness and muscle inflammation seen in biopsies, they also have distinct differences in their presentation and underlying mechanisms. Patients with PM and DM usually experience a gradual onset of symmetrical proximal muscle weakness, often accompanied by elevated serum creatine kinase levels. Electromyography and magnetic resonance imaging (MRI) reveal similarities in both diseases. In DM, skin biopsies from affected areas display limited inflammatory cell infiltration at the dermo-epidermal junction, resembling the histopathological features of cutaneous lupus. These dermal infiltrates include activated T cells and immune complex deposition along vessel walls in the dermis. In con...

 Polymyositis (PM) and Dermatomyositis (DM) are autoimmune myopathies characterized by inflammation and weakness of proximal muscles with extra muscular manifestations. In DM, there is muscle weakness associated with skin rash. Although both these disorders share some common clinical and histological features like muscle weakness and inflammatory infiltrates. ·        According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, the estimated prevalence of polymyositis and dermatomyositis (PM/DM) in the US is 7 to 23 per 100,000 persons, and the incidence is approximately 1.2 to 19 million persons at risk per year. The incidence of myositis is increasing over time due to an increase in the detection rate. Thelansis’s “Polymyositis (PM) and Dermatomyositis (DM) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug uti...